No Evidence of Disease Activity Achieved in Multiple Sclerosis with Dimethyl Fumarate

Hospitals Offer Urgent Care Tailored For Cancer Patients
May 16, 2017
The Liver Grows by Day, Shrinks by Night
May 16, 2017
Show all

No Evidence of Disease Activity Achieved in Multiple Sclerosis with Dimethyl Fumarate

Research looks into the most beneficial way to use the medication dimethyl fumarate.

Post hoc data analysis of the DEFINE and CONFIRM trials showed that a higher percentage of patients with relapsing-remitting multiple sclerosis (RRMS) achieved no evidence of disease activity (NEDA) with delayed-release dimethyl fumarate (DMF) compared with placebo. The results were published in the European Journal of Neurology.1

NEDA is a relatively new composite outcome that is being used more often to measure therapeutic response in multiple sclerosis. NEDA is comprised of 3 factors: no clinical relapse, no disability progression measured by the Expanded Disability Status Scale (EDSS) for 12 weeks, and no evidence of disease activity on magnetic resonance imaging (MRI).

Read full article: No Evidence of Disease Activity Achieved in Multiple Sclerosis with Dimethyl Fumarate

Read Full Article: No Evidence of Disease Activity Achieved in Multiple Sclerosis with Dimethyl Fumarate

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.